Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Autologous CMV-specific CTLs + Temozolomide |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Autologous CMV-specific CTLs | Autologous cytomegalovirus-specific cytotoxic T-lymphocytes | Autologous CMV-specific CTLs are patient-derived cytotoxic T-lymphocytes (CTLs) that are reactive to cytomegalovirus (CMV), which potentially increase immune response to CMV-related tumors (PMID: 22421947). | ||
| Temozolomide | Temodar | Methazolastone|TMZ | Chemotherapy - Alkylating 18 | Temodar (temozolomide) is a dacarbazine analog and cytotoxic alkylating agent (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02661282 | Phase Ib/II | Autologous CMV-specific CTLs + Temozolomide | Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma | Completed | USA | 0 |